SABITALKS / Artificial Intelligence in Health & Disease: Machine Learning-Based Drug Response, Resistance, and Personalized Treatment Models
Dr. Emel Sokullu is going to be at SABITALKS on January 13, 2026 at 14:00, and will give a presentation titled “Artificial Intelligence in Health & Disease: Machine Learning-Based Drug Response, Resistance, and Personalized Treatment Models” The event will take place in person.
Location: Istanbul Medipol University North Campus / Building C, 1st Floor – Senate Room.
https://goo.gl/maps/JDDjygVtFLWiPiMJA
*Participants from outside SABITA must fill in the participation form.
Artificial Intelligence in Health & Disease: Machine Learning-Based Drug Response, Resistance, and Personalized Treatment Models
This presentation will explore how artificial intelligence and machine learning-based approaches can play a transformative role in diagnosis, prognosis, and treatment response prediction for heterogeneous and treatment-resistant brain tumors such as glioma and neurodegenerative diseases. Specifically, the joint analysis of multi-modal data sources (MR images, histopathology, molecular biomarkers, and clinical parameters) enables more accurate differentiation of glioma subtypes and the development of patient-specific treatment strategies.
The presentation will discuss the use of deep learning and classical machine learning methods in glioma image analysis, tumor heterogeneity, progression prediction, and treatment response prediction; it will also discuss how these models can be linked to drug response, chemotherapy, and resistance mechanisms in targeted therapies. The integration of AI-supported models into clinical decision support systems will be positioned as a tool that enhances the physician’s decision rather than replacing it.
Additionally, the translational potential of AI-supported drug and treatment systems will be evaluated within the framework of university-hospital-industry collaborations, taking into account the clinical validity, generalizability, and ethical-privacy dimensions of the developed models. The presentation will conclude with a roadmap for the transition of artificial intelligence from research to clinical practice in the field of glioma and neurodegenerative disease perspectives.
Emel Sokullu
Assist. Prof.
Biophysics at Koç University School of Medicine, Researcher at KUTTAM
Emel Sokullu has been graduated from the Department of Physics Engineering, Istanbul Technical University. During her graduate years, she worked on biomaterials, polymers, nerve cell culture, ion implantation, and surface modification as a part of projects of Alabama A&M University Research Institute and Lawrence Berkeley National Laboratory. Afterward, she continued her studies at Bioacoustic MEMs in Medicine Labs at MIT Harvard Medical School Health Science and Technology to continue her postdoctoral research in which she took part in brain tissue studies that utilize 3D hydrogels. In 2016, she established SOLAB R&D company within Dokuz Eylul University Health Technopark within the scope of TUBITAK BIGG program support. SOLAB company has received numerous awards from various organizations such as TTGV and Acıbadem University Incubation Center. Emel Sokullu, who was selected for the Royal Academy of Engineering Leaders of Innovation program, continues her research studies at the Department of Biophysics, Koç University Faculty of Medicine and Koç University Translational Medicine Research Center (KUTTAM) since September 2019. Emel Sokullu is a member of the Society for Neuroscience, FENS, Turkish Biophysics Association and IEEE.